Strides Pharma Science Ltd · NSE:STAR

Strides Pharma Science — Investor Day (December 2019)

86 slides from Strides Pharma Science's investor day presentation, Dec 5, 2019

  1. Slide 1: Advancing Affordable Biopharma

    Advancing Affordable Biopharma

  2. Slide 2: Stelis Leadership Team today

    Stelis Leadership Team today Milan Doshi Dr. Roger Lias SVP & Global Biosimilars CEO Business Development Joe Thomas Biju Mathew Outgoing CEO SVP & Head of Quality Minh Tran Molly McGlaughlin SVP & Head of Manufacturing SVP & Global Lead CDMO Anand Khedkar Sachin Jaiswal SVP & Head of R&D Finance He

  3. Slide 3: Evolution: Compelling opportunity, differentiated model

    EVOLUTION. Compelling opportunity Differentiated Model $160m+ investments Strong progress What started as a sub-set of our speciality business has now been built into a fully integrated biopharmaceutical business with world-class capabilities. Biologics is a long gestation business and Stelis is at

  4. Slide 4: Invested over $160m to position Stelis as a differentiated business

    Invested over $160m to position Stelis as a differentiated business having diverse income streams UNIQUE SCIENTIFIC DOMAIN NICHE DIVERSIFIED PLATFORM EXPERIENCE EXPERTISE PORTFOLIO INCOME STREAMS 01 02 03 04 05  State-of-the art R&D and small  Talented scientific &  Clone development  Focusing o

  5. Slide 5: Strategic oversight by an Independent Board

    Strategic oversight by an Independent Board with cross functional and wide experience Ghiath Sukhtian Deepak Vaidya Founder & Chairman, GMS Chairman and Independent Director 50+ years experience and founder of MS pharma, Tabuk Pharmaceuticals, He is a fellow member of the Institute of Chartered Acco

  6. Slide 6: Led by an experienced team with global experience

    Led by an experienced team with global experience across leading biotech companies Name Work Experience Dr. Roger Lias 30+ years Joe Thomas 30+ years Minh Tran 25+ years Anand Khedkar 25+ years Milan Doshi 25+ years Biju Mathew 25+ years Molly McGlaughlin 25+ years page Strictly Private and Confiden

  7. Slide 7: Stelis Growth Strategy

    A two-pronged strategy to drive profitable growth… Stelis Growth Globally Compliant Biosimilars Strategy High-End CDMO services • Niche but commercially attractive biologics • Fully integrated, multi-capable facilities and skill sets representing important disease categories for end-to-end biopharma

  8. Slide 8: Growth outlook of global pharmaceutical industry

    …in the industry where biotech is set to become $500b opportunity in next 5 years Key Points ◼ Global biologics market is expected to grow much faster than the chemical drugs market ─ Share of biologics in the global pharma market expected to increase from c.19% in 2015 to c.30% in 2025 ◼ Strong gro

  9. Slide 9: Affordable bio-therapeutics underpins our strategy

    Affordable bio-therapeutics underpins our strategy INDUSTRY CHALLENGES O U R A P P ROACH AT S TEL IS • Low penetration of biologics in EM/RoW ▪ Strategic selection & partnering on biosimilar development • Cost of biologics un-affordable to patients opportunities across regulated & emerging markets.

  10. Slide 10: Complexity higher than generics, continued barriers to entry

    Complexity remains significantly higher than generics, hence continued barriers to entry Biosimilars Generics Time 7-8 years 2-3 years Product Cost $30 - $100 million $1 - $10 million Development Probability of 50-75% ~90% Success Technical Barriers to entry High Low Requirement Requirement for PK/P

  11. Slide 11: Portfolio: Differentiated products

    PORTFOLIO Differentiated products Complements affordability De-risked development. Well designed GTM. The strategic investments in our biosimilar program have put us in a sweet spot with our advanced assets ready to enter phase-3 trials & a disruptive technology for insulins. Strictly Private and Co

  12. Slide 12: An attractive initial pipeline for Stelis

    An attractive initial pipeline for Stelis to validate full spectrum of capabilities Commercial Market Clone Lab scale Process Molecule Innovator Indication Phase 1 Phase 3 Market Current Stage Rights Opportunity Selection similarity Char. ▪ Dossier preparation for submission with EMA as biosimilar.

  13. Slide 13: Rh-Teriparatide

    Rh-Teriparatide: Biosimilar to Forteo®/ Forsteo®

  14. Slide 14: Biosimilar to Forteo/Forsteo - niche osteoporosis treatment

    Biosimilar to Forteo®/Forsteo® - a niche treatment for osteoporosis 01 02 03 04 PRODUCT FORM& MARKET OUR CURRENT INDICATION OPPORTUNITY DIFFERENTIATORS STATUS • Indication : Treatment of • Forteo/Forsteo® leads the • Same recombinant • Completed EU approval women with post market amongst treatment e

  15. Slide 15: Reusable & disposable device for global market needs

    Reusable & disposable device for addressing global market needs innovator reusable device disposable device CE marked reusable device developed • Developed on proven autopen® platform by owen mumford UK • CE certificate received from SGS, UK based notified body • Developed for 24 month in-use period

  16. Slide 16: Stelis Sodium Hyaluronate

    Stelis Sodium Hyaluronate: First non-avian, non-cross-linked, high molecular weight low-volume single injection for knee osteoarthritis

  17. Slide 17: Completed global development for osteoarthritic pain product

    Completed global development for a compelling product in the management of osteoarthritic pain 01 02 03 04 PRODUCT FORM& MARKET OUR CURRENT INDICATION OPPORTUNITY DIFFERENTIATORS STATUS • Form: Intra-articular • Growing prevalence of • First non-avian, non-cross- • Completed global development of th

  18. Slide 18: HA market shift towards single injection

    HA market largely driven by 3 injections with a structural shift towards single injection OPPORTUNITY FOR HA BASED TREATMENT SHIFT IN DEMAND TOWARDS SINGLE INJECTIONS Inj. Regime% CY2015 CY2018 CY2023 18-23 CAGR 5 injections ~300 ~349 ~300 ~-3% 3 Injections ~850 ~1,123 ~1,350 ~5% ~$2.5b 1 injectio

  19. Slide 19: Hyalostel One superior to current market leading products

    Stelis Hyalostel OneTM is superior to the current market leading products stelis biopharma Sanofi Aventis Ferring Pharma Anika Therapeutics Zimmer Biomet (market leader) avian derived avian derived source non-avian non-avian non-avian (chicken comb) (chicken comb) visco non-cross linked chemical cro

  20. Slide 20: Exceeds the market leaders in physico-chemical properties

    Exceeds the market leaders in physico-chemical properties NON CROSS-LINKED & HIGH MOLECUL AR WEIGHT Only commercially developed non-cross linked single-injection product with no toxic cross linkers Superior to market leader synvisc-one®, with significantly higher concentration and lower volume LOW V

  21. Slide 21: Disrupting the industry paradigm in insulins

    Disrupting the industry paradigm in insulins with low cost technology platform

  22. Slide 22: Insulin low cost technology platform

    Disrupting the industry paradigm in insulins with low cost technology platform #1 #2 #3 #4 LOWEST PRODUCT GLOBAL PRODUCT OPTIMISED FASTER TIME TO COST QUALITY DEVELOPMENT COST MARKET • Highest Yield with optimised • Industry leading product • Controlled cost of program • In market for market insulin

  23. Slide 23: Global Insulin Opportunity continues to expand

    Global Insulin Opportunity continues to expand with ~500 million diabetic patients GLOBAL SCENARIO KEY OPPORTUNITIES FOR NEW PLAYERS LIKE STELIS • Making Insulin and its analogs accessible to patients at affordable cost is our goal. • High Protein expression platforms & efficient purification proces

  24. Slide 24: Recombinant Insulins remain standard of care

    Recombinant Insulins will continue to be ‘standard of care’ for foreseeable future 01 02 03 04 PRODUCT FORM& MARKET OUR CURRENT INDICATION OPPORTUNITY DIFFERENTIATORS STATUS • Developing insulin and • Rapid market growth in • Foray into the highly • Planned region-wise clinical insulin analogs with

  25. Slide 25: BIRAC Grant-in-Aid validates technology proposition

    BIRAC Grant-in-Aid for Stelis Insulin-Glargine validates technology proposition  Received formal confirmation of $ 3Mn Grant-In-Aid from BIRAC under funding line between Government of India and World Bank for Accelerating Discovery to Development of Biopharma.  Stelis amongst few companies to have

  26. Slide 26: EMA & FDA regulations favouring our insulin strategy

    EMA & FDA regulations and recent initiatives favouring our insulin strategy Changing Regulatory landscape Europe United States • Europe has actively adopted biosimilar products • Recent notification from US-FDA suggests that a due to their impact on cost of healthcare. comparative immunogenicity stu

  27. Slide 27: Global GTM strategy with flexible business model

    Global GTM strategy mapped for all assets with a flexible business model

  28. Slide 28: Flexible business models for faster Go To Market access

    Flexible business models for faster Go To Market access B2C WITH OWN FRONT END Where the asset is fully owned and unencumbered, giving Stelis the unrestricted ability to roll-out via own front-ends in key markets (APAC, SEA) B2C WITH JV Joint venture with partners for the development, registration a

  29. Slide 29: Advanced licensing discussions ongoing

    Significant advanced stage discussions ongoing for licensing, our funnel is well aligned with the current development stage of product R H - T E R I PA R AT I D E H YA L O S T E L O N E T M INS U L IN A NA LOG S Market Ongoing Market Ongoing Market Ongoing Region Region Region Opportunity($m) discus

  30. Slide 30: Capabilities: Best-in-class R&D platform

    CAPABILITIES. Best-in-class R&D platform. Cost-efficient development. Globally compliant practices. Dual purpose capabilities. 22,000 sq. ft. R&D centre at Jigani, Bangalore dedicated to the development of recombinant biologics and formulations. Facility is designed to support both microbial and mam

  31. Slide 31: Product and process development as per global standards

    PRODUCT AND PROCESS DEVELOPMENT AS PER GLOBAL STANDARDS Scientists Houses 100+ scientists Key Capabilities R&D area Occupies 22,000+ Square feet • Clone development of Analytical, PD and FD labs • Upstream process development • Downstream process development Merck Partnership • Formulation developme

  32. Slide 32: Designed for smooth scale-up and technology transfer

    Advanced DS Process Scale-Up lab to bridge R&D and Commercial scale DESIGNED WITH BEST-IN-CLASS TECHNOLOGIES FOR SMOOTH SCALE- UP AND TECHNOLOGY TRANSFER Key Capabilities • Partnership with Merck Life Sciences on Process Technologies and Training • Equipment with same geometric aspects as in commerc

  33. Slide 33: cGMP Process Scale Up and Quality Control Labs

    cGMP Process Scale Up and Quality Control Labs to support clinical development  cGMP manufacturing of Microbial and Mammalian products up to 50L scale  Analytical Methods and Bioassay Development  Clinical product filling for all injectable formats  Execution of stability studies of DS and DP as

  34. Slide 34: High end manufacturing capabilities

    ESTABLISHING LONG TERM SUCCESS WITH HIGH END MANUFACTURING CAPABILITIES • Fully integrated and flexible microbial and mammalian manufacturing platforms for drug substances and fill finish of drug products • Designed to offer comprehensive CDMO services and own IP biopharma products with regulatory c

  35. Slide 35: Fast and flexible large-scale manufacturing facilities

    Fast and flexible large-scale manufacturing facilities for commercial production Key Capabilities • Faster, more flexible and cost-effective way of producing biologics drug substances and drug products • Hybrid Microbial platform with conventional SS fermenter for fermentation and single-use and con

  36. Slide 36: Global standards org wide

    Quality fabric integrated across the entire chain from development to commercial manufacturing GLOBAL ORG WIDE INTERNAL MANAGEMENT STANDARDS IMPLEMENTATION CONTROLS OVERSIGHT • Adopting global regulatory • Leveraging 20 + years of • Internal & External audits • Quality Forum (QSR) at the site requir

  37. Slide 37: Stelis BioSource: one stop solution CDMO

    CDMO SERVICES Stelis BioSource : A one stop solution for customers in a business environment constrained by high quality biotech capacities Operated as Stelis BioSource, we are a one-stop shop with comprehensive capabilities from Cell line and Process Development through to scale up, cGMP manufactur

  38. Slide 38: End to end biological services

    Offering end to end biological services from early stage to late stage development to commercial manufacturing R&D CAPABILITIES PROCESS SCALE UP MANUFACTURING • Upstream development • Microbial upstream • DS manufacturing • Downstream development • Mammalian upstream • Formulations, aseptic fill and

  39. Slide 39: Biopharma contract manufacturing is a $26b opportunity

    Biopharma contract manufacturing is a $26b Opportunity constrained by significant capacity shortages Key Drivers for growth 01. $26b Hedge Risk Biopharmaceutical companies often outsource to balance risk and buy time until key milestones 02. Capacity constraints Opportunity by 2023 given the growing

  40. Slide 40: Trends favour inflows into growth for new players

    Trends continue to favour dollar inflows into growth for new players with significant capabilities EVOLVING VOLUME FLEXIBLE SIMPLIFIED CAPACITY TECHNOLOGY TRENDS PLATFORMS SUPPLY CHAINS CONSTRAINTS 1 2 3 4 5 • The “world” of • Production volumes are • Reducing economy of • Market need for • 2019 fin

  41. Slide 41: The CMC Biologics market landscape

    The CMC Biologics market landscape- India Accounts for 12% of the global outsourced projects assigned *Average Commercial Contract is $20M-$30MUSD/Year for 5 years $100-150M Total MARKET BY REGION B I G P H A R M A / B I OT E C H CMC BIOLOGICS MARKET PL ACE BY CLINICAL PHASE US, Canada & Western Eur

  42. Slide 42: Significant growth in large molecule outsourcing

    Significant growth visible in the large molecule and biotech space for outsourcing ANNUAL REVENUE GROWTH BY SEGMENT OUTSOURCED MARKET SEGMENTS *Stelis BioSource™ Pipeline has 30+ potential Clinical research 9% opportunities with mix of global players Large Pharma/Biotech Drug Product 4% VA L U E C H

  43. Slide 43: Stelis BioSource uniquely positioned in competitive market

    Stelis BioSource is uniquely positioned in otherwise a competitive market place STELIS CENTER OF EXCELLENCE CDMO OFFERING CLONAL CELL LINES Clonal cell line development (CHO, Large Market Leaders SP2/0, NS0, e. Coli, Pichia) A L L T I M E R E G U L AT O R Y C O M P L I A N C E COMPETITIVE L ANDSCAPE

  44. Slide 44: Gated activities for all programs

    Stelis is a one-stop solution with capabilities for single cycle development Project Management Project initiation Clone Selection and process Lab Scale Consistency Mfg Process Lock Cell Lines development CELL LINE PROCESS PROCESS GMP DEVELOPMENT DEVELOPMENT SCALE-UP MANUFACTURING DOE and QbD high P

  45. Slide 45: Key investments completed. Near term revenue visibility

    OUTCOME Key investments completed. Near term revenue visibility. Diverse income streams. Significant Value Creation. With major investments already made into development platform, laying a decisive go-to- market strategy, we are now poised to build a sustainable business with high margins & promisin

  46. Slide 46: Stelis Value Chain

    Multiple pillars for growth and profitability with risk mitigated cashflow streams • Cost-effective process technology developed in the US with higher Insulin platform technology yield, greater recovery, and high purity vs. competition • FY21- Break even at operating level with marginal Opex under-

  47. Slide 47: ~$40m additional infusion from Strides into Stelis

    With ~$40m additional infusion from Strides, Stelis is designed for significant value Current Ownership Ownership after infusion of investments Partners #shares $Value %holding #shares $Value %holding Strides 4,06,434 34.7 42.8% 7,26,409 74.6 54.1% Minority investors 5,44,091 56.4 57.2% 6,15,910 70.

  48. Slide 48: Thank You

    Thank You Strictly Private and Confidential

  49. Slide 49: Steriles v2.0

    Ster les v2.0 Recreating Value in Speciality Injectables | December 2019 Strictly Private and Confidential

  50. Slide 50: December 05, 2019: end of Agila non-compete period

    December 05, 2019: An exciting day for Strides as we complete our six year non-compete period on Agila transaction today Strictly Private and Confidential

  51. Slide 51: Extensive experience. Proven outcomes.

    Extensive experience. Proven outcomes. We are known to have created disruptive value with Agila-our speciality injectable business that was sold to Mylan as an undisputed “market leading” speciality injectable platform.

  52. Slide 52: Significant experience in building Agila

    Significant experience in building Agila as a global specialty injectable platform… ROBUST R&D PLATFORM COMPLIANCE RECORD  Built domain expertise in product  Unblemished 15 year track record of development: Liposomal, nanoparticle , 65 inspections until closure of emulsions, peptides, colloidal tr

  53. Slide 53: Agila 1.0 achieved all its strategic outcomes

    …which resulted in $1.6b value for all stakeholders TOWARDS THE END OF 2012 , AGILA 1.0 HAD ACHIEVED ALL ITS  Leading player in a niche and difficult-to-operate injectables segment STRATEGIC OUTCOMES  Best-in-class manufacturing and operations infrastructure VALUE  Market-leading track record of

  54. Slide 54: Generics Injectables. Continued growth opportunity.

    Generics Injectables. Continued growth opportunity. High barriers to entry led by complex capabilities, high operational & capital cost and compliance requirements make injectables a compelling play

  55. Slide 55: Generic injectables market growing at 13% CAGR

    The opportunity in generic injectables remains exciting, and the market continues to grow @ 13% CAGR CONTINUED REMAINS A SUPPLY OPPORTUNITIES TO MARKET GROWTH SPECIALISED PLAY SHORTAGES CREATE A NEW NICHE • Global Opportunity of • No major player has • 60% of the drug • Opportunity to develop produc

  56. Slide 56: Steriles v2.0 lighter, faster, better

    Steriles v2.0 is designed to be lighter, faster, better and yet more valuable Leveraging our strengths, rich experience and the high points of our version 1.0, we plan to rekindle our steriles business and develop a robust B2C led global injectable franchisee that bodes well with the growing industr

  57. Slide 57: Key elements of our B2C led Strategy in Steriles 2.0

    Key elements of our B2C led Strategy in Steriles 2.0 HIGH FOCUS ON DIFFERENTIATED VIRTUAL & COMPELLING PRODUCT PRODUCT DEVELOPMENT PORTFOLIO 01 02 03 04 05 LEVERAGING RICH ASSET LIGHT REGULATED MARKET DOMAIN GLOBAL FOCUS WITH EXPERIENCE IN MANUFACTURING REVENUES THROUGH INJECTABLES STRATEGY OWN FRON

  58. Slide 58: Experienced team with 100+ years of domain experience

    An experienced team with 100+ years of domain experience and proven track record in Agila/Mylan Project Management and Technical Leadership Quality & Compliance Regulatory & IP Portfolio Strategy Manufacturing • Strategic oversight by • Driven by Sundhar CK, ex- • Oversight by Biju Mathew, • Group c

  59. Slide 59: Value Chain: scale up as we grow

    Virtual model for development with lesser products , lighter infrastructure and focused outcomes Use of platform technologies through strategic partnerships to develop differentiated products to solve for Readiness of the hybrid fill-finish aseptic increased drug stability, high bioavailability and

  60. Slide 60: Phased portfolio with $10b+ market opportunity

    Developing a phased portfolio with $10b+ market opportunity that mirrors our strategic progression DIFFERENTIATED PRODUCTS • Use of platform technologies through strategic partnerships to develop differentiated products to solve for Clinical, R&D, Manufacturing and Supply chain challenges • Partners

  61. Slide 61: B2C led regulated market model

    Purely a B2C led regulated market model with better economics potential over Agila 1.0  Strategy designed around own front- end for B2C led growth  Focus on unrestricted ability to roll- out products via own front-end in the US and other regulated markets  Front end focus to have better economics

  62. Slide 62: Steriles Version 2.0 in a nutshell

    Steriles Version 2.0 in a nutshell: Leveraging our rich domain experience. Virtual development of the portfolio. Lesser products with global orientation. Lighter infrastructure. Phased investments B2C led regulated market strategy. Mirrored equity ownership structure to Stelis. (Strides will have ~5

  63. Slide 63: Reset. Resurgent. Strides Growth Strategy

    Reset. Resurgent. Strides Growth Strategy | December 05, 2019

  64. Slide 64: Global generic industry witnessing structural changes

    The global generic industry is witnessing the most dramatic times leading to structural changes and creating a new normal for the market players

  65. Slide 65: Dramatic shift in business environment for global generics

    Dramatic shift in the business environment for the global generics play STRUCTURAL CHANGES TRANSITION TO GX-GX COMPLIANCE EMERGING TRENDS IN THE US GENERICS MODEL IN EX-US MARKETS OVERHANG IN THE MARKET • Generics industry witnessing a • Structural shift of generics model in • Companies have witness

  66. Slide 66: Consolidation strategy of large players has not played out

    The consolidation strategy of large players has not played out to plan, giving new opportunities for emerging players with supply efficiencies and customer centricity # ANDA withdrawals in the US #drugs discontinued in the US in 2018 ANDA launches as a % of approvals(est) 64 606 50% 45% 40% 30% 252

  67. Slide 67: Strides strategy reset over last 18 months

    Over the last 18 months, the Strides strategy has been reset to adapt to the changing environment and yet leading into resurgent growth with right sized balance sheet

  68. Slide 68: "Less for more" approach with better financial outcomes

    Focusing on a “less for more” approach with better financial outcomes C O N T R A R I A N S T R AT E G I E S C O N C E N T R AT E D O P E R AT I O N S BETTER FINANCIAL OUTCOMES Blitz-scaling in the US markets • Achieved operational excellence with • Adjusting for the exit of our operations in • Inve

  69. Slide 69: Contrarian strategy in US achieving 6x growth

    Contrarian strategy in US, unlike competition. Achieving 6x growth in <4 years. Benefiting from the proactive strategy to blitz scale when most incumbents are down sizing or exiting.

  70. Slide 70: Resurgent growth through own front end

    Resurgent business growth through own front end and carefully selected products FOCUS APPROVALS PORTFOLIO PIPELINE TEAM ~$20M ~$57M IN Q4FY18 IN Q2FY20 Focus on mature products 100+ ANDAs filed with Strong Commercial Pipeline of 40 products Strong go to market that are high technology 67+ approvals

  71. Slide 71: Value oriented portfolio strategy

    Well designed value oriented portfolio strategy for our business progression MARGIN SURPLUS ALLOWING STEPPING UP THE VALUE CHAIN • Strategy designed around in-licensing programs with 505(b)(2) orientation • Product development, licensing & supply agreement entered with SUDA, an AU R&D Co. for its no

  72. Slide 72: Growing front end P&L with key commercialized products

    A growing front end P&L with key commercialized products having no price erosion or consistent market share PRODUCTS WITH RANK #1 (% MS) PRODUCTS WITH RANK 2 & 3 (% MS) Ketoconazole Tablets 77% Ergocalciferol Capsules 41% Calcitriol Capsules 31% Methoxsalen Soft Gels 66% PEG 3350/Electrolytes - 26%

  73. Slide 73: Our US Business Value chain

    Invested in building blocks to double our current business visibility to a potential ~$800m US business • Biosimilar PTH (Teriparatide) targeting Osteoporosis with < 4 competitors $150m-$250m • Drug-device Sod. Hyaluronate Single Injection – only 3 other mkt leading single inj. Brands, opportunity i

  74. Slide 74: Fast growth in other regulated markets, $20b opportunity

    Fast growth in often neglected other regulated markets. Tapping $20b opportunity with portfolio fungibility across the key markets-Europe, Australia, Canada and South Africa.

  75. Slide 75: Low-key pharmaceutical growth markets fastest growing segment

    Low-key pharmaceutical growth markets are the fastest growing segment for Strides 01 03 Foray into new markets Low investment high return with a small base and opportunity through limited front end presence portfolio maximization in UK approach $20m $32m Q119 Revenues In Q2’20 02 A complex mix of P&

  76. Slide 76: Turning around businesses acquired at low investment value

    Matured markets drives 80% revenue delivering more than Company EBITDA. Focus on turning around businesses acquired at a low investment value Core Strategy 3x growth in UK with EBITDAs higher than company average • Organic growth with 95+ registrations and strategic focus to sell products through ow

  77. Slide 77: Reset strategy for emerging markets and global access

    While regulated markets have been course corrected, our reset strategy for emerging markets and global access markets continues to be work in progress

  78. Slide 78: FY21 could see traction from new institutional launches

    Challenges in the emerging markets and institutional business continue, FY21 could see traction from the new launches in institutional business R E S E T S T R AT E G Y G O A L S • Initiated our course correction strategy for emerging market & institutional business in FY19 to focus on achieving str

  79. Slide 79: Strengthening CXO suite and strategic advisory

    Strengthening CXO suite and strategic advisory with new arrivals and robust governance framework

  80. Slide 80: Leveraging rich global expertise of industry stalwarts

    Leveraging rich global expertise of the industry stalwarts Venkat Iyer, Global Tech Operations Dr. Aqeel Fatmi, R&D Strategy GP Singh , US Business Prabir Jha , Leadership transformation • 35+ years experience in formulations, • 37+ years of experience in • Senior Pharmaceutical Executive / Advisor

  81. Slide 81: A Strong Corporate leadership team

    A Strong Corporate leadership team with rich global pharmaceutical experience Arun Kumar Badree Komandur Raju Subramanyam Managing Director & Executive Director & CFO Head-Global Manufacturing Group CEO Shashank Sinha Umesh Kale VK Singh CEO - International Business Chief of Quality Services Chief B

  82. Slide 82: Focus to reclassify Puducherry facility, recalibrate quality

    Highest focus to reclassify Puducherry facility & recalibrate the quality fabric of Strides Role changes determined to regain our industry leading standards with compliance • Significant changes made to quality and compliance framework given the changing regulatory paradigm and the unfavourable Pudu

  83. Slide 83: New CXO leadership to drive stronger outcomes

    New CXO leadership to drive stronger strategic & business outcomes Raju Subramanyam, Head Global Mfg Sanjay Singh, CHRO VK Singh, Chief Business Officer Anjani Kumar, Chief IT Officer • Providing overall leadership to the • Leading the people centre and own all its • An accomplished industry leader

  84. Slide 84: Strategic growth engines in place

    With strategic growth engines in place, our efficient execution could result in Strides achieving significant revenue size with industry leading profitability and return ratios.

  85. Slide 85: Create significant value through differentiated platforms

    Well designed to create significant value through differentiated platforms C O N T I N U E D VA L U E C R E AT I O N BIOTECH , CHC & PRIVATE LABEL BIOTECH • Niche but commercially attractive biologics representing important disease categories STERILE INJECTABLES • Multiple pillars for growth and pro

  86. Slide 86: Thank You

    Thank You

Strides Pharma Science — Investor Day (December 2019) on 6ix